Clinigen Group plc which already acquired the rights outside of the US in July 2018 , announced today that it has signed an agreement with Novartis to acquire the US rights to Proleukin (aldesleukin, human recombinant interleukin-2) for up to $210m in cash, consisting of an upfront and deferred payments along with future
According to Shaun Chilton, Group Chief Executive Officer, Clinigen: “Proleukin is an excellent fit within our oncology and infectious disease medicines as well as diversifying our wider portfolio – it will be the largest product in the portfolio in terms of current sales. The product has significant potential for revitalisation, which will provide further breadth and diversity to the portfolio and material increases in revenues.
“For Clinigen as a whole, Proleukin creates an ideal platform to expand our existing footprint in the higher value US market and therefore enables us to exploit other opportunities across the business. This follows our acquisition last year of CSM and iQone which strengthened our Continental European footprint.
According to IQVIA, Proleukin generated $60 million in revenue in the United States for the year leading up to June 30, 2018. Proleukin (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma (metastatic RCC). In certain markets Proleukin is also indicated for the treatment of adults with metastatic melanoma.
This deal with Novartis follows acquisitions of CSM and iONE Healthcare by Cinigen in September 2018.